USE OF PHARMACEUTICAL COMPOSITION CONTAINING EPIDERMAL GROWTH FACTOR (EGF) FOR PREVENTING DIABETIC LIMB AMPUTATION

USE OF A PHARMACEUTICAL COMPOSITION, WHICH CONTAINS EPIDERMAL GROWTH FACTOR (EGF), PREFERABLY IN AN INJECTABLE FORM AND TO BE ADMINISTERED THROUGH INFILTRATIONS INSIDE AND AROUND CUTANEOUS CHRONIC ISCHEMIC ULCERATIVE WOUNDS AS TO PREVENT DIABETIC LIMB AMPUTATION. IT MAY BE ADMINISTERED ON RECENTLY INDUCED SURGICAL POST-AMPUTATION SURFACES, OR DAMAGED TISSUE AREAS BY THE PROCESS OF ACUTE REPERFUSION WITH OXYGENATED BLOOD, FOLLOWING PROLONGED ISCHEMIA. THIS ALLOWS FOR THE PREVENTION OF SURGICAL RE-INTERVENTIONS, THUS ASSISTING IN LIMB PRESERVATION. WITH THE USE OF THIS COMPOSITION THE CELLULAR MICROENVIRONMENT IS IMPROVED, WHICH RENDERS THE CELLS MORE VIABLE AND WITH ENHANCED DEFENSE CAPABILITIES TO ORCHESTRATE THE HEALING PROCESSES OF ISCHEMIC WOUNDS. THE USE OF THIS COMPOSITION ALSO STIMULATES CELL PROLIFERATION. THIS COMPOSITION IS PARTICULARLY USEFUL IN THOSE PATIENTS BEARING A DIABETIC FOOT ULCER. THE USE OF THE PHARMACEUTICAL COMPOSITION DESCRIBED HEREIN IS APPLICABLE TO HUMAN, EXPERIMENTAL AND VETERINARY MEDICINE, BEING PARTICULARLY RELEVANT FOR ANGIOLOGY AND VASCULAR SURGERY, DERMATOLOGY, PLASTIC AND RECONSTRUCTIVE SURGERY, AND GERIATRICS. THE PHARMACEUTICAL COMPOSITION CAN BE USED IN THOSE SUBJECTS AFFLICTED WITH RECALCITRANT ULCERS ASSOCIATED TO MACRO AND LOR MICROVASCULAR DEFICITS, TO THOSE SUBJECTS WITH INSUFFICIENT VENOUS AND / OR LYMPHATIC FUNCTIONAL FAILURE, AND IN ALL THOSE INDIVIDUALS BEARING PROBLEM WOUNDS WITH REFRACTORINESS TO HEAL.